Skip to main content

Advertisement

Table 1 Therapy profiles

From: HIV-1 mutational pathways under multidrug therapy

Therapy profiles
Compounds N Duration # Previous
3TC AZT 259 549 (21,3515) 3 (0,28)
d4T DDI 149 553 (40,3291) 5.2 (0,19)
TDF FTC 123 284 (28,1122) 5.9 (0,25)
3TC d4T 115 646 (19,3508) 4.5 (0,18)
3TC TDF 96 311 (27,1360) 7.4 (0,20)
3TC DDI 61 590 (43,2268) 8.6 (1,37)
3TC ABC 52 397 (40,1140) 6.5 (0,18)
AZT 50 379 (1,1939) 2 (0,12)
3TC ABC AZT 50 437 (28,1423) 4.6 (0,19)
AZT DDI 49 413 (57,1408) 5.1 (0,17)
  1. The data in the current study contains 119 unique combinations of reverse transcriptease inhibitors. The 10 most common combinations are listed here, along with the number of subjects receiving them, mean (range) duration in days, and mean (range) number of previous therapies when administered. Note that these therapies may also have included protease inhibitors. The full table is given in the supplement.